Literature DB >> 4621748

Treatment of experimental allergic encephalomyelitis with encephalitogenic basic proteins.

S Levine, R Sowinski, M W Kies.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4621748     DOI: 10.3181/00379727-139-36174

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


× No keyword cloud information.
  8 in total

1.  Suppression of experimental allergic encephalomyelitis in guinea-pigs with poly-L-lysine.

Authors:  E Chelmicka-Szorc; B G Arnason
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

2.  Experimental allergic encephalomyelitis. Production by myelin basic protein adsorbed on particulate adjuvants.

Authors:  S Levine; R Sowinski; R Gruenewald; M W Kies
Journal:  Immunology       Date:  1972-10       Impact factor: 7.397

3.  Treatment of experimental allergic encephalomyelitis with myelin basic protein: which route is best?

Authors:  S Levine; R Sowinski
Journal:  Neurochem Res       Date:  1984-10       Impact factor: 3.996

4.  Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin).

Authors:  D H Boehme; H Umezawa; G Hashim; N Marks
Journal:  Neurochem Res       Date:  1978-04       Impact factor: 3.996

5.  Chronic relapsing experimental allergic encephalomyelitis: CNS plaque development in unsuppressed and suppressed animals.

Authors:  C S Raine; U Traugott; S H Stone
Journal:  Acta Neuropathol       Date:  1978-08-07       Impact factor: 17.088

Review 6.  Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis.

Authors:  Shailesh R Satpute; Malarvizhi Durai; Kamal D Moudgil
Journal:  Semin Arthritis Rheum       Date:  2008-01-04       Impact factor: 5.532

Review 7.  Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review.

Authors:  V K Tuohy
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

8.  Antigen-driven bystander suppression after oral administration of antigens.

Authors:  A Miller; O Lider; H L Weiner
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.